ரோபர்ட்டா ஹெர்மன் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ரோபர்ட்டா ஹெர்மன். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ரோபர்ட்டா ஹெர்மன் Today - Breaking & Trending Today

Phillips 66 (PSX) Q1 2021 Earnings Call Transcript

Phillips 66 (PSX) Q1 2021 Earnings Call Transcript
Motley Fool Transcribers
© The Motley Fool
Logo of jester cap with thought bubble.
Phillips 66 (NYSE: PSX)
Operator
Welcome to the First Quarter 2021 Phillips 66 Earnings Conference Call. My name is Hilary and I will be your operator for today s call. [Operator Instructions]
I will now turn the call over to Jeff Dietert, Vice President, Investor Relations. Jeff, you may begin.SPONSORED:
10 stocks we like better than Phillips 66
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade,
Motley Fool Stock Advisor, has tripled the market. ....

United States , City Of , United Kingdom , San Francisco , Cedar Bayou , Corpus Christi , Contra Costa County , Port Arthur , Santa Maria , Phil Gresh , Bob Herman , Tim Roberts , Matthew Blair , Manav Gupta , Neil Mehta Goldman Sachs , Jason Gabelman Cowen , Matthew Blair Tudor , Theresa Chen , Paul Cheng Scotiabank , Brian Mandell , Kevin Mitchell , Doug Leggate , Jason Gabelman , Mark Lashier , Jeff Dietert , Theresa Chen Barclays ,

Investegate |Renalytix AI PLC Announcements | Renalytix AI PLC: Exclusive option agreement

surrounding a comprehensive panel of novel biomarkers in kidney disease

NEW YORK, April 14, 2021
-
Renalytix AI plc
(LSE: RENX) (NASDAQ: RNLX) announced today that it has entered into an exclusive option agreement with Joslin Diabetes Center for patent filings on certain additional novel biomarkers in kidney disease for development and deployment in the KidneyIntelX in vitro prognostic platform.

These novel biomarkers have the potential to provide additional clinical utility for understanding early disease progression and risk of kidney failure, therapeutic response, and the mechanistic pathways of kidney disease beyond the inflammatory and tubular injury markers that are currently captured by KidneyIntelX. RenalytixAI plans to begin evaluating these novel biomarkers in expanded clinical validation studies beginning in the second half of 2021. ....

United States , Paul Mcmanus Lianne Cawthorne , James Mccullough , Fergus Fleming , Nicholas Moore , Alex Price , Roberta Herman , Daniel Adams , Andrzej Krolewski , Gary Clarence , Centers For Disease , Exchange Commission , Joslin Diabetes Center , Drug Administration , Harvard Medical School , Investec Bank , Joslin Diabetes Center Build , Proprietary Kidney Biomarker , Chief Technology Officer , Joslin Diabetes , Section Head , Senior Investigator , Diabetic Kidney , Nominated Adviser , Joint Broker , Kidney Disease ,